Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors
Globe Newswire (Wed, 8-Jul 2:00 AM ET)
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
Globe Newswire (Mon, 29-Jun 7:30 AM ET)
Market Chameleon (Thu, 18-Jun 6:35 AM ET)
Globe Newswire (Wed, 17-Jun 12:36 PM ET)
Compass Pathways Elects Kathleen Tregoning to Board of Directors
Business Wire (Thu, 28-May 6:30 AM ET)
Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update
Globe Newswire (Wed, 13-May 4:05 PM ET)
Globe Newswire (Tue, 5-May 4:05 PM ET)
Market Chameleon (Tue, 21-Oct 7:08 AM ET)
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Spero Therapeutics trades on the NASDAQ stock market under the symbol SPRO.
As of July 8, 2026, SPRO stock price climbed to $2.19 with 101,245 million shares trading.
SPRO has a beta of 0.05, meaning it tends to be less sensitive to market movements. SPRO has a correlation of 0.00 to the broad based SPY ETF.
SPRO has a market cap of $126.78 million. This is considered a Micro Cap stock.
In the last 3 years, SPRO traded as high as $3.22 and as low as $.51.
The top ETF exchange traded funds that SPRO belongs to (by Net Assets): VTI, VXF, IWC, DFAS, DFMC.
SPRO has underperformed the market in the last year with a return of -24.5%, while the SPY ETF gained +20.7%. In the last 3 month period, SPRO fell short of the market, returning -18.0%, while SPY returned +12.8%. However, in the most recent 2 weeks SPRO has outperformed the stock market by returning +1.9%, while SPY returned +1.1%.
SPRO support price is $2.06 and resistance is $2.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SPRO shares will trade within this expected range on the day.
